INTRAVENOUS IMMUNOGLOBULIN FOR IN-VITRO FERTILIZATION FAILURE

The aim of this study was to determine the effectiveness of intravenou s (i.v.) immunoglobulin (Ig) for treatment of individuals experiencing failure after in-vitro fertilization (IVF) and embryo transfer. A tot al of 29 women with unexplained infertility who failed to become pregn ant after IVF/embryo transfer were divided into two groups based on pe rformance in previous IVF cycles: 16 women had fertilization of greate r than or equal to 50% of oocytes retrieved and/or produced greater th an or equal to 3 embryos each cycle and 13 had fertilization of < 50% of oocytes retrieved and/or produced <3 embryos each cycle. Each woman had received at least 12 transferred embryos (95th percentile for suc cessful IVF patients) or had experienced two or more biochemical pregn ancies without ultrasonic confirmation of implantation during previous IVF/embryo transfer attempts. All women received i.v. Ig 500 mg/kg pr ior to the next embryo transfer. Only one of the 13 (8%) women with su boptimal fertilization and embryo yield became pregnant in the treatme nt cycle. Of 16 women who had previously had fertilization of at least 50% of oocytes retrieved and produced at least three embryos, nine (5 6%) became pregnant in the treatment cycle. The difference in pregnanc y rates between the two groups is significant (P = 0.02). Intravenous Ig is useful in the treatment of unexplained IVF failure in women who have oocyte fertilization rates greater than or equal to 50% and gener ate at least three embryos per cycle.